211 related articles for article (PubMed ID: 30739368)
1. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
[TBL] [Abstract][Full Text] [Related]
2. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
[TBL] [Abstract][Full Text] [Related]
3. High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Sanai FM; Alghamdi AS; Afghani AA; Alswat K; AlZanbagi A; Alghamdi MN; AlMousa A; Aseeri M; Assiri AM; Babatin MA
Liver Int; 2018 Aug; 38(8):1395-1401. PubMed ID: 29288514
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Londoño MC; Riveiro-Barciela M; Ahumada A; Muñoz-Gómez R; Roget M; Devesa-Medina MJ; Serra MÁ; Navascués CA; Baliellas C; Aldamiz-Echevarría T; Gutiérrez ML; Polo-Lorduy B; Carmona I; Benlloch S; Bonet L; García-Samaniego J; Jiménez-Pérez M; Morán-Sánchez S; Castro Á; Delgado M; Gea-Rodríguez F; Martín-Granizo I; Montes ML; Morano L; Castaño MA; de Los Santos I; Laguno M; Losa JE; Montero-Alonso M; Rivero A; de Álvaro C; Manzanares A; Mallolas J; Barril G; González-Parra E; García-Buey L
PLoS One; 2019; 14(9):e0221567. PubMed ID: 31550267
[TBL] [Abstract][Full Text] [Related]
5. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
Rosenthal P; Narkewicz MR; Yao BB; Jolley CD; Lobritto SJ; Wen J; Molleston JP; Hsu EK; Jonas MM; Zha J; Liu L; Leung DH
Adv Ther; 2020 Jul; 37(7):3299-3310. PubMed ID: 32451952
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Poordad F; Sedghi S; Pockros PJ; Ravendhran N; Reindollar R; Lucey MR; Epstein M; Bank L; Bernstein D; Trinh R; Krishnan P; Polepally AR; Unnebrink K; Martinez M; Nelson DR
J Viral Hepat; 2019 Aug; 26(8):1027-1030. PubMed ID: 30980576
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Shiffman ML; Rustgi V; Bennett M; Forns X; Asselah T; Planas Vila R; Liu L; Pedrosa M; Moller J; Reau N
Am J Gastroenterol; 2016 Jun; 111(6):845-51. PubMed ID: 27045929
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
Wu J; Huang P; Fan H; Tian T; Xia X; Fu Z; Wang Y; Ye X; Yue M; Zhang Y
Virol J; 2019 Jan; 16(1):11. PubMed ID: 30654809
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
[TBL] [Abstract][Full Text] [Related]
10. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A; De Luca M; Melazzini M; Montilla S; Trotta MP; Petta S; Puoti M; Sangiovanni V; Messina V; Bruno S; Izzi A; Villa E; Aghemo A; Zignego AL; Orlandini A; Fontanella L; Gasbarrini A; Marzioni M; Giannini EG; Craxì A;
Infection; 2018 Oct; 46(5):607-615. PubMed ID: 29808463
[TBL] [Abstract][Full Text] [Related]
12. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
13. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
Aygen B; Demirtürk N; Yıldız O; Çelen MK; Çelik İ; Barut Ş; Ural O; Batırel A; Mıstık R; Şimşek F; Asan A; Ersöz G; Türker N; Bilgin H; Kınıklı S; Karakeçili F; Zararsız G; Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT
Turk J Gastroenterol; 2020 Apr; 31(4):305-317. PubMed ID: 32412901
[TBL] [Abstract][Full Text] [Related]
14. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients.
Fofiu C; Boeriu A; Coman F; Fofiu A; Panic N; Bulajic M; Dobru D
Ann Hepatol; 2019; 18(1):137-143. PubMed ID: 31113582
[TBL] [Abstract][Full Text] [Related]
15. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
[TBL] [Abstract][Full Text] [Related]
17. High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.
El Kassas M; Alboraie M; Omar H; El Latif YA; Algaber MA; El Tahan A; El Halwagy H; Afify S; Elserafy M; Elsaeed K; Doss W
J Med Virol; 2022 Feb; 94(2):667-674. PubMed ID: 30950069
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
Welzel TM; Hinrichsen H; Sarrazin C; Buggisch P; Baumgarten A; Christensen S; Berg T; Mauss S; Teuber G; Stein K; Deterding K; van Bömmel F; Heyne R; John C; Zimmermann T; Lutz T; Schott E; Hettinger J; Kleine H; König B; Hüppe D; Wedemeyer H
J Viral Hepat; 2017 Oct; 24(10):840-849. PubMed ID: 28342229
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Lawitz E; Makara M; Akarca US; Thuluvath PJ; Preotescu LL; Varunok P; Morillas RM; Hall C; Mobashery N; Redman R; Pilot-Matias T; Vilchez RA; Hézode C
Gastroenterology; 2015 Oct; 149(4):971-80.e1. PubMed ID: 26170136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
